by Denkstrom
All storiesStudy: CAR-T cell therapy improves walking test in 26 SPS patients

Study: CAR-T cell therapy improves walking test in 26 SPS patients

A new study shows that walking ability in a walking test improved significantly in 26 people with stiff-person syndrome after a single CAR-T cell therapy, with a median improvement of 45.6 percent. There is currently no approved treatment for the rare autoimmune disease.

For the primary endpoint, the time needed to complete the 25-foot walking test decreased by a mean of 7.69 seconds from baseline by week 16. According to the study authors, stiff-person syndrome is a progressive autoimmune disease involving muscle stiffness and painful spasms that leads to substantial disability. A randomized study has already demonstrated a statistically significant benefit from intravenous immunoglobulins, although their effect is limited and sometimes wanes. According to Deutsches Ärzteblatt, the very rare disease affects one to two people per million and is triggered by autoantibodies against the enzyme glutamic acid decarboxylase or a glycine receptor, both of which are produced by nerve cells.

The study is called KYSA-8 and is listed in the ClinicalTrials.gov trial registry as an open-label, single-arm, multicenter phase 2 study without a comparison group. Of the 27 participants recorded in the registry, 26 were treated, with a median age of 56 years, including 16 women; people aged 18 to 75 with antibody-positive SPS whose previous immunomodulatory treatments had not been sufficiently effective in the investigators' assessment were enrolled at three U.S. sites from September 2024 to May 2025. Exclusions included patients who had been bedridden for more than three months or had previously received a stem cell transplant. The study was funded by Kyverna Therapeutics, which, according to its own disclosure, was involved in the design, conduct, data analysis and interpretation, as well as decisions concerning the manuscript; several authors disclosed personal fees, patent applications or employment with the company. In July 2026, the study was marked as completed in the registry.

stiff-person-syndrom

Low-grade cytokine syndrome and neurotoxicity

According to the study, the most common severe adverse event was grade 3 or 4 neutropenia in 5 of the 26 people treated. Low-grade cytokine release syndrome occurred in 24 of 26 patients, and a neurotoxicity syndrome, also low-grade, occurred in three of 26; both types of event resolved without lasting harm. According to the authors, all 26 people treated remained without additional immunomodulatory or immunosuppressive SPS medication through the last available follow-up. However, the median follow-up for the primary analysis was only 6.5 months.

One year after the infusion

After one year of follow-up, the CU Anschutz School of Medicine reported sustained improvements on October 21, 2026: All 26 treated patients completed the one-year study and needed a median of 49 percent less time for the walking test than before treatment. Of twelve patients who had initially needed a walking aid, eight completed the test without one. 24 of 26 patients remained without SPS immunotherapy. In 65 percent of patients, the immune cells targeted by the treatment had begun to return by the one-year mark, but the clinical improvements were maintained, according to the statement. Study leader Amanda Piquet, director of the autoimmune neurology program at the CU Anschutz School of Medicine, described the duration of the effect as a key question, according to a report on the so-called living drug.

How robust are the results

A consensus paper by EBMT, ISCT and JACIE published in October 2026 in the journal The Lancet Rheumatology describes CAR-T cells as a promising option for severe, treatment-refractory autoimmune diseases since 2021, but also points to continuing research needs. Immunologist Carl June warned that it was far too early to speak of a definitive cure; moreover, not enough people had yet been treated to assess all possible side effects.

Plans announced for FDA approval application

Stanford neurologist Paul George described the results presented in April 2026 as “very exciting” and, according to a report on the new cell therapy, called them progress for a disease without good treatment options. According to the CU Anschutz School of Medicine statement, Kyverna Therapeutics announced plans to complete the rolling submission of its application for FDA approval in the fourth quarter of 2026. If approved, the treatment could become the first FDA-approved therapy specifically for stiff-person syndrome and the first FDA-approved CAR-T cell therapy for an autoimmune disease, according to the school. According to a STAT report, FDA officials in February 2026 explicitly recommended long-term studies of CAR-T use against autoimmune diseases because of possible cancer or fertility risks, as are standard for gene therapies and CAR-T cells used in oncology. Whether the autoimmune disease returns in some patients remains an open question.